Retention rate of Levetiracetam in children with intractable epilepsy at 1 year

Peake, Deirdre; Mordekar, Santosh R.; Gosalakkal, Jayaprakash A.; Mukhtyar, B.; Buch, Stephan; Crane, Jack; Wheway, R.; Rittey, Christopher D.; Donnelly, Jonathan P.; Whitehouse, William P; Philip, Sunny

doi:10.1016/j.seizure.2006.12.001

Cited by 36 publications

(35 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Grosso et al reported that 31% of their patients after three months and 15% after 12 months were seizure free (15). Peake et al reported 14% seizure free patients after two and six months and 5% after 12 months (14). According to the results of these studies, it can be concluded that duration of follow-up is influenced by the percentage of patients being seizure free.…”

Section: Discussionmentioning

confidence: 95%

“…Grosso et al (15) and Peake et al (14) found a decrease in the number of patients being seizure free during follow-up. Grosso et al reported that 31% of their patients after three months and 15% after 12 months were seizure free (15).…”

Section: Discussionmentioning

confidence: 95%

“…Moreover, LEV administration in children was associated with low discontinuation rates due to adverse effects. The most common reported adverse effects were mild and reversible (2,(11)(12)(13)(14)(15). Although previous trials demonstrated the efficacy of LEV both in adults and children, safety and efficacy of LEV in infancy remains ascertained.…”

Section: Contextmentioning

confidence: 99%

See 2 more Smart Citations

Add-on Levetiracetam in Children With Refractory Epilepsy: A Systematic Review

Abbaskhanian

Shahmohammadi

2016

J Pediatr Rev

View full text Add to dashboard Cite

Context: Recently, new anti-epileptic drugs are marketed to be used as an add-on to the traditional drugs in children with refractory epilepsy. Levetiracetam is a second-generation of new anti-epileptic drugs with unknown precise mechanism of action in brain and synaptic vesicle in children with drug resistant epilepsy. Herein, the efficacy and safety of add-on levetiracetam in children with refractory epilepsy is reviewed.Evidence Acquisition: A literature review was performed on efficacy and safety of add-on Levetiracetam in children with refractory epilepsy using international databases with the following terms: levetiracetam, refractory epilepsy, drug resistant epilepsy, seizures/epilepsy, children/pediatric. All articles related to add-on levetiracetam in children with refractory epilepsy written in English and published from 2000 to 2015 were included. The title and abstracts of 542 articles were assessed, of which, 488 were excluded. The full texts of the other 54 articles were assessed for relevance. Results:Of the nine eligible articles, 1036 patients aged ≤ 18 years were identified. Male patients (52%) were more prominent than female ones. Five articles reported that levetiracetam therapy appeared more effective against localization-related than generalized epilepsy. The dosage of levetiracetam ranged from 6 to 70 mg/kg/day, with a mean of 43.2 mg/kg/day based on the mean doses reported by four of nine reviewed articles. The mean duration of follow-up was 39 weeks (ranging from 8 -144 weeks). Administration of levetiracetam was effective in 42.24% of the patients (responders with >50% decrease in seizure frequency), of whom 11.8% had become seizure free. The mean number of anti-epileptic drugs tried before introducing levetiracetam treatment was 4.4 (ranging 1 -20). The most frequent side effects were psychological and behavioral changes (11.1%), followed by agitation (9.2%) and sleep disturbances (6.7%). Conclusions:The current review demonstrated that levetiracetam, as an add-on therapy, is an effective and well-tolerated antiepileptic drug, associated with reversible and no serious side effects, to control seizure frequency of childhood refractory epilepsy.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 95%

Section: Contextmentioning

confidence: 99%

See 1 more Smart Citation

Add-on Levetiracetam in Children With Refractory Epilepsy: A Systematic Review

Abbaskhanian

Shahmohammadi

2016

J Pediatr Rev

View full text Add to dashboard Cite

show abstract

“…Положительный эффект достиг-нут в 60 % случаев. Процент удержания на терапии через 1 год составил 49 % (с учетом того, что исследо-вание включало только детей с тяжелыми резистент-ными формами эпилепсии, данный показатель очень высок) [77].…”

Section: детской неврологииunclassified

Efficacy and Tolerability of Levetiracetam (Keppra®) in the Treatment of Epilepsy: Review of Literature

Мухин¹,

Пылаева²

2015

Rus. ž. det. nevrol.

View full text Add to dashboard Cite

“…[2] Yeni AEİ'lardan levetirasetamın çocuk ve erişkinlerin parsiyel başlangıçlı, idiyopatik ya da jeneralize nöbetlerindeki etkinliği ve gü-venirliği kabul edilmesine rağmen, yenidoğanda özellikle prematürelerde kullanımı ile ilgili sınırlı çalışma vardır. [3,4] Bu yazıda klasik AEİ'lara cevap vermeyen dirençli nöbetleri olan yedi günlük ikiz prematüre olgularda LEV'yi kullanma sonuçlarımız sunuldu.…”

Section: Introductionunclassified

Levetirasetam for the Treatment of Refractor Neonatal Seizures

Keleş¹,

Gebeşçe²,

Yazgan³

2012

Epilepsi

View full text Add to dashboard Cite

ÖzetKonvülsiyonlar yenidoğan döneminde, özellikle prematürelerde sık görülür. Konvansiyonel antiepileptiklerin güvenirliliği ve etkinliği ayrın-tılı olarak araştırılmıştır. Buna rağmen, en sık kullanılan fenobarbitalin bile daha önce bilinmeyen apopitoz gibi uzun dönem yan etkileri yeni fark edilmektedir. Oysa yeni antiepileptiklerden levetirasetamın çocuk ve erişkinlerin parsiyel başlangıçlı, idiyopatik ya da jeneralize nöbet-lerindeki etkinliği ve güvenirliği ile ilgili birçok çalışma yapılmıştır. Ancak yenidoğanlarda özellikle prematürelerdeki çalışmalar sınırlıdır. Bu yazıda klasik antiepileptiklerere cevap vermeyen, ancak levetirasetamla nöbetleri kontrol altına alınan yedi günlük ikiz prematüre olgular sunuldu. Her iki hastanın uzun süreli takiplerinde nöbet ve ilaca bağlı her hangi bir yan etki gözlenmedi.Anahtar sözcükler: Dirençli nöbet; levetirasetam; yenidoğan. SummaryConvulsions are observed commonly in newborns and especially in premature babies. The afety and efficiency of conventional antiepileptic drugs have been extensively investigated. But long term side effects like apoptosis are newly recognized even with the the most commonly used antiepilectic drug, phenobarbital. Much research is related to the safety and efficiency of levetiracetam, one of the recent antiepileptic drugs, used in partial onset idiopathic or generalized seizures of adults and children. However, research on newborns, especially premature newborns is limited. In this paper we present two cases involving seven day newborn premature twins treated with refractory seizures. Seizures were controlled only with levetiracetam therapy. We did not observe any long term side effects which can be related to levetiracetam or seizures in a long term follow up of both patients.

show abstract

Retention rate of Levetiracetam in children with intractable epilepsy at 1 year

Abstract: Our results confirm the efficacy and tolerability of LEV in children with refractory epilepsies and demonstrate good response and retention rates at 12 months. It represents the largest cohort of paediatric patients published so far on LEV with a 1-year follow-up.

Cited by 36 publications

References 22 publications

Add-on Levetiracetam in Children With Refractory Epilepsy: A Systematic Review

Add-on Levetiracetam in Children With Refractory Epilepsy: A Systematic Review

Efficacy and Tolerability of Levetiracetam (Keppra®) in the Treatment of Epilepsy: Review of Literature

Levetirasetam for the Treatment of Refractor Neonatal Seizures

Contact Info

Product

Resources

About